Physician profile
Amy Romick
NPI 1447771290
$4,525.18
in general payments reported to CMS, 2019-2025
22 companies · $2,707 in 2025
The $2,707 reported for 2025 was more than what 96% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.23 · 2023: $166 · 2024: $1,621 · 2025: $2,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,493.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $928.59 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $735.97 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $667.23 | 2024 | |
| Alkermes, INC. | $529.92 | 2024-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $258.75 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $253.25 | 2025 | |
| Lundbeck LLC | $239.61 | 2024-2025 | Vyepti, Rexulti |
| Vanda Pharmaceuticals INC. | $184.02 | 2024-2025 | Fanapt, Hetlioz |
| Genentech USA, INC. | $135.40 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Acadia Pharmaceuticals INC | $121.32 | 2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $115.36 | 2024-2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $77.64 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $44.71 | 2024-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $37.90 | 2024 | Trintellix |
| Sk Life Science, INC. | $33.32 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $33.30 | 2024 | Daxxify |
| Neurelis, INC. | $23.42 | 2024 | Valtoco |
| Novartis Pharmaceuticals Corporation | $23.28 | 2024 | |
| Argenx US, INC. | $23.17 | 2024 | Vyvgart Hytrulo |
| Ipsen Biopharmaceuticals, INC | $21.00 | 2025 | Dysport |
| Merck Sharp & Dohme LLC | $20.73 | 2023 | Belsomra |
| Medtronic, INC. | $17.29 | 2024 | Percept PC Brainsense |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Romick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.